Fulton Bank N.A. boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 5.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,433 shares of the medical research company’s stock after buying an additional 640 shares during the quarter. Fulton Bank N.A.’s holdings in Amgen were worth $1,969,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the stock. Jackson Grant Investment Advisers Inc. increased its holdings in Amgen by 0.6% during the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock valued at $104,000 after buying an additional 4 shares during the period. Conservest Capital Advisors Inc. grew its holdings in Amgen by 0.4% in the second quarter. Conservest Capital Advisors Inc. now owns 3,130 shares of the medical research company’s stock worth $539,000 after purchasing an additional 13 shares during the last quarter. M Holdings Securities Inc. grew its holdings in Amgen by 0.6% in the first quarter. M Holdings Securities Inc. now owns 2,825 shares of the medical research company’s stock worth $463,000 after purchasing an additional 18 shares during the last quarter. Kovitz Investment Group Partners LLC grew its holdings in Amgen by 1.2% in the first quarter. Kovitz Investment Group Partners LLC now owns 3,223 shares of the medical research company’s stock worth $529,000 after purchasing an additional 38 shares during the last quarter. Finally, AMG Funds LLC grew its holdings in Amgen by 0.4% in the first quarter. AMG Funds LLC now owns 10,089 shares of the medical research company’s stock worth $1,655,000 after purchasing an additional 41 shares during the last quarter. 78.09% of the stock is currently owned by institutional investors.

Several equities analysts have issued reports on AMGN shares. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and issued a $189.00 price target on shares of Amgen in a report on Friday, June 30th. BidaskClub raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a report on Friday, June 23rd. Credit Suisse Group set a $177.00 price target on shares of Amgen and gave the stock a “hold” rating in a report on Friday, July 14th. Morgan Stanley lifted their price target on shares of Amgen from $183.00 to $184.00 and gave the stock an “overweight” rating in a report on Tuesday, June 13th. Finally, Deutsche Bank AG reaffirmed a “hold” rating and issued a $174.00 price target (up from $172.00) on shares of Amgen in a report on Wednesday, July 26th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $186.14.

ILLEGAL ACTIVITY WARNING: “Fulton Bank N.A. Raises Position in Amgen Inc. (AMGN)” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/09/24/fulton-bank-n-a-raises-position-in-amgen-inc-amgn.html.

Amgen Inc. (NASDAQ:AMGN) traded down 0.47% on Friday, reaching $185.76. 2,275,630 shares of the company were exchanged. The stock has a 50-day moving average price of $175.99 and a 200 day moving average price of $169.31. The stock has a market capitalization of $135.54 billion, a price-to-earnings ratio of 16.92 and a beta of 1.35. Amgen Inc. has a 52 week low of $133.64 and a 52 week high of $191.10.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The company had revenue of $5.81 billion during the quarter, compared to analysts’ expectations of $5.67 billion. During the same quarter last year, the business earned $2.84 EPS. The business’s revenue was up 2.1% on a year-over-year basis. Analysts forecast that Amgen Inc. will post $12.57 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Thursday, August 17th were paid a $1.15 dividend. This represents a $4.60 annualized dividend and a dividend yield of 2.48%. The ex-dividend date of this dividend was Tuesday, August 15th. Amgen’s dividend payout ratio (DPR) is presently 41.93%.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.